Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

Screening for HIV in pregnancy eliminates vertical transmission

Screening for HIV in pregnancy eliminates vertical transmission

Canada has almost eliminated mother-to-child HIV transmission, known as vertical transmission, in recent years by ensuring that all women have the opportunity to be screened for HIV in pregnancy and that women with the disease receive treatment before giving birth. [More]
Study: Cash to stay in school did not reduce HIV risk among young women in South Africa

Study: Cash to stay in school did not reduce HIV risk among young women in South Africa

A Phase III, individually randomized trial has found conditional cash transfers for school attendance did not reduce the risk of HIV among high-school aged women in South Africa, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada. [More]
InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax, a biopharmaceutical company specialized in research and development of therapeutic and diagnostic solutions for major infectious and chronic diseases, today announced the overall results of its Phase I/IIa clinical study of its VAC-3S immunotherapy, which is currently in development. [More]
Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals. [More]
Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Beckman Coulter Life Sciences today announces an expansion of its CARES (Cellular Accessible Retroviral Evaluation Systems) Initiative at the 2015 International AIDS Society (IAS) Conference, being held at the Vancouver Convention Centre from July 19-22, 2015 in Vancouver, Canada. CARES focuses on providing innovative solutions for the monitoring of HIV and AIDS treatment in Africa. [More]
Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Results from HPTN 067, a Phase II, randomized, open-label study, demonstrate most study participants had higher coverage of sex events and better adherence when they were assigned to the daily dosing arm, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada. [More]
Study findings provide basis for potential development of new methods to control HIV infection

Study findings provide basis for potential development of new methods to control HIV infection

Lower levels of cholesterol in certain immune cells--a result of enhanced cholesterol metabolism within those cells--may help explain why some HIV-infected people are able to naturally control disease progression, according to research that will be presented in a poster at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada, and the pre-conference 2015 Towards an HIV Cure Symposium. [More]
Canadian researchers discover how HIV evades the body's antiviral responses

Canadian researchers discover how HIV evades the body's antiviral responses

A Canadian research team at the IRCM in Montreal, led by molecular virologist Eric A. Cohen, PhD, made a significant discovery on how HIV escapes the body's antiviral responses. The team uncovered how an HIV viral protein known as Vpu tricks the immune system by using its own regulatory process to evade the host's first line of defence. [More]
Mylan announces launch of generic Namenda Tablets in U.S.

Mylan announces launch of generic Namenda Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda Tablets. [More]
New report highlights key success in global response to preventing AIDS in women, children

New report highlights key success in global response to preventing AIDS in women, children

The Elizabeth Glaser Pediatric AIDS Foundation applauds today's announcement from the Joint United Nations Programme on HIV/AIDS that the goal of providing 15 million people with lifesaving antiretroviral therapy (ART) by 2015 has been met nine months ahead of schedule. [More]
Mylan announces launch of Bexarotene 75mg Capsules in U.S.

Mylan announces launch of Bexarotene 75mg Capsules in U.S.

Mylan N.V. today announced the U.S. launch of Bexarotene 75mg Capsules, which is the generic version of Valeant's Targretin Capsules. This product is indicated for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy. [More]
TSRI study reveals alternative approach to current anti-HIV strategies

TSRI study reveals alternative approach to current anti-HIV strategies

HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the virus and clinical progression to AIDS. [More]
Southern Research receives $22 million to support HIV cure initiative

Southern Research receives $22 million to support HIV cure initiative

Southern Research has been awarded a seven-year contract of up to $22 million to support research that could contribute to the cure of HIV disease. Under this contract, Southern Research will develop and standardize assays that quantitate latent reservoirs of HIV. [More]
Researchers complete participants’ enrollment in Phase III trial of vaginal ring for HIV prevention

Researchers complete participants’ enrollment in Phase III trial of vaginal ring for HIV prevention

In a first for HIV prevention, an international team of researchers have completed follow-up of participants enrolled in a pivotal Phase III trial that tested the safety and effectiveness of a vaginal ring for preventing HIV in women. [More]
Innovations in AIDS efforts should be leveraged to meet future global health challenges, says UNAIDS-Lancet Commission

Innovations in AIDS efforts should be leveraged to meet future global health challenges, says UNAIDS-Lancet Commission

Countries most affected by HIV must focus on stopping new HIV infections and expanding access to antiretroviral treatment or risk the epidemic rebounding, urges a major new report from the UNAIDS and Lancet Commission. [More]
Implementation of needle exchange programs can prevent HIV outbreaks in Indiana

Implementation of needle exchange programs can prevent HIV outbreaks in Indiana

Congress needs to immediately lift the ban on federal funding for needle exchange programs to counter the threat of HIV outbreaks among injection drug users like the one that has seen an alarming number of new cases erupt in a single rural Indiana county. [More]
Single difference in HIV's genetic code influences progression of disease

Single difference in HIV's genetic code influences progression of disease

In a finding that furthers the understanding of human immunodeficiency virus (HIV), researchers from Children's Hospital Los Angeles discovered two locations where a single difference in HIV's genetic code altered the way the virus infected the cell, thereby influencing the progression of the disease. [More]
Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies. [More]
WHO and World Bank Group: 400 million people do not have access to essential health services

WHO and World Bank Group: 400 million people do not have access to essential health services

A World Health Organization and World Bank Group report launched today shows that 400 million people do not have access to essential health services and 6% of people in low- and middle-income countries are tipped into or pushed further into extreme poverty because of health spending. [More]
HIV-infected transgender women in US have unmet basic needs, less likely to achieve viral suppression

HIV-infected transgender women in US have unmet basic needs, less likely to achieve viral suppression

A new CDC study that combines 3 years of data to produce nationally representative estimates characterizing HIV-infected adults receiving care in the U.S. shows that those who identify as transgender women are significantly less likely to adhere to anti-HIV medication regimens and to achieve viral suppression. [More]
Advertisement